Judy Clarke – IR Doug Michels – President and Chief Executive Officer Ron Spair – COO and CFO

Ed Shenkan – Needham & Co. John Putnam – Dawson James Jeff Frelick – Lazard Capital Markets Dave Turkaly – Susquehanna Financial Group Caroline Corner – Pacific Growth Aaron Lindberg – William Smith & Co.

Good day everyone and welcome to the OraSure Technologies 2008 first quarter financial results conference call and simultaneous webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period. (Operator instructions) For opening remarks and introductions, I'll now turn this call over to Judy Clarke at OraSure Technologies. Please go ahead.

Good afternoon everyone and thank you for joining us today. I'd like to begin by telling you that OraSure Technologies issued a press release at approximately 4:00 p.m. Eastern Time today regarding our 2008 first quarter financial results and certain other matters. The press release is available to you on our Web site at www.orasure.com or by calling 610-882-1820. If you go to our Web site, the press release can be accessed by opening the Investor Relations page and clicking on the link for News Releases. This call is also available real-time on our Web site and will be archived there for seven days. Alternatively, you can listen to an archive of this call until midnight May 13, 2008 by calling 800-642-1687 for domestic or 706-645-9291 for international. The access code is 43942293. With us today are Doug Michels, President and Chief Executive Officer; and Ron Spair, Chief Operating Officer and Chief Financial Officer. Doug and Ron will begin with opening statements which will be followed with question and answer sessions. Before I turn the call over to Doug, I must also remind you that this call may contain certain forward looking statements, including statements with respect to revenues, expenses, profitability, earnings per share and other financial performance, product development, performance, shipments and markets and regulatory filings and approvals. Actual results could be significantly different. Factors that could affect results are discussed more fully in the SEC filings of OraSure Technologies, including its annual report on Form 10-K for the year ended December 31, 2007, its quarterly reports on Form 10-Q and its other SEC filings. Although forward looking statements help to provide complete information about future prospects, listeners should keep in mind that forward-looking statements may not be reliable. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after this call. With that, I'd like to turn the call over to Doug Michels.

Thank you, Judy, and good afternoon everyone and welcome to our first quarter 2008 earnings conference call. Ron Spair will begin this afternoon's call with a review of our first quarter results followed by a discussion of our second quarter and full year 2008 financial guidance. Earlier today, we issued a press release detailing our first quarter results. As you can see from this release, our first quarter results financial performance was in line with guidance. However, since our last call, there have been a number of unexpected developments in our business and the markets that we serve which necessitate an adjustment in our guidance for the rest of the year. Following Ron's remarks, we will open the floor for your questions on these developments. After that, I will provide an update on several aspects of our business, including our principal strategic initiatives and our efforts to grow the business. We'll conclude by again opening the floor for your questions. So, now let's go to Ron's financial overview.

Thanks, Doug, and good afternoon everyone. First, I'll start with a brief review of the first quarter results. Total revenues for Q1 were in line with guidance at $18.1 million. Increased sales of OraQuick ADVANCE, our insurance risk assessment products and professional cryo products were offset by expected decreases in revenue from our OTC cryosurgical wart removal products and substance abuse testing products. A 6% growth in our infectious disease revenues was the result of continued strong sales of our OraQuick ADVANCE rapid HIV test. Sales to public health during the quarter increased 45% over 2007 as a result of continued growth in our base business and increased sales related to the Centers for Disease Control and Prevention's efforts to increase HIV testing among populations disproportionately affected by HIV. These increases were partially offset by the absence of bulk purchases by the CDC and the Substance Abuse and Mental Health Services Administration, SAMHSA, that were recorded in the year ago period. Our sales to Abbott decreased 11% as a result of their ordering patterns for the U.S. hospital market. International sales of OraQuick decreased 14% compared to the same period in 2007 largely as a result of a 25% decrease in revenues from Africa. Our cryo revenues during Q1 experienced an overall decrease of 41% compared to 2007. This was expected and forecasted as this decrease was primarily due to the absence of U.S. OTC sales resulting from the termination of our distribution relationship with Prestige Brands at the end of 2007. First quarter 2007 sales to Prestige were $2.1 million. Our international OTC sales for the first quarter of 2008 were $1.6 million, a 22% decrease from 2007 that largely resulted from reduced sales in Europe due to the variability of distributor purchasing patterns. First quarter cryosurgical sales to…

(Operator instructions) Your first question comes from the line of Ed Shenkan. Ed Shenkan – Needham & Co.: Hey, Ron.

Hey, Ed. Ed Shenkan – Needham & Co.: On Genomma, for the second quarter and for 2008, what kind of revenues do you expect?

We are actually not expecting any revenues in the second quarter from Genomma and would expect those revenues to be present but skewed more towards the end of the year when they would restart. Ed Shenkan – Needham & Co.: Okay. And on the international side, you mentioned in Africa that there was some changes that took place, I think you said for funding. Could you just explain kind of what's going on and then what expectations are going forward in Africa?

Sure. We remain convinced that Africa is a very attractive market in which to participate. However, there was an unexpected change with a funding source dedicated to Madagascar, one of our largest clients there. And as the tail end of the quarter approached, they informed us of a change from one funding source to another. This funding source was not prepared to fund OraQuick purchases. And as we moved out into April and had further discussions with them, we believe at this point – moment in time that there will be no further purchases until we are able to secure dialog with this funding source and look at and hopefully work with them to advance the OraQuick test as part of their funded testing program. Ed Shenkan – Needham & Co.: So, your comments are specific to Madagascar, not to the rest of the African continent, is that right?

That's correct. That's right on the funding. That's correct. Ed Shenkan – Needham & Co.: Tell us about the rest of the continent. How is it looking forward for Africa?

I think Ed, this is Doug, so our private sector business continues to grow and we continue to add new accounts there, which we are very pleased with. We're working on some major new initiatives with particularly East African countries that are very well funded and this refers back to the comment Ron made, unfortunately, given the civil unrest that's occurred over the last couple of months it's made even travel to those countries difficult. Although in our discussions with government leaders and program leaders, they're still very committed to expanding their testing programs and to using OraQuick. So for us, this is a setback, obviously. Difficult to forecast some of these political issues, but we continue to be very bullish on the opportunity. Ed Shenkan – Needham & Co.: On the city and state orders in the U.S., with the increased CDC funding this year, are you finding that funding is cannibalizing what the cities and states would have ordered otherwise or how are things playing out?

I'm going to address that a little bit in the back half of the call, but we continue to do very well on our direct sales to public health as Ron mentioned. I'll mention later our views on the CDC deployment, which is a bit delayed although the CDC has indicated that they're going to refund the program for the fiscal year 2009 and our position with the jurisdictions continues to be very strong. So again, this is somewhat of a timing related issue, but very strong position both there as with the city jurisdictions as well. Ed Shenkan – Needham & Co.: I'll leave time for other questions. Thanks.

You bet.

Your next question comes from a line of John Putnam with Dawson James. John Putnam – Dawson James: Thanks. I guess I was trying to understand what's going on with the CDC a little bit better and I didn't realize you'd be speaking about that later, Doug. But I guess I'm just wondering why things are slower given the enthusiasm that seemed to be in order a couple of back around the turn of the year.

Yes, the enthusiasm hasn't diminished. We are six months into the CDC program. The sites got their funding at the end of September. And as we mentioned, the jurisdictions – the monies were earmarked both for infrastructure and capacity building as well as for testing. We indicated numerous times in previous calls that we didn't expect to see a substantial ramp until the second or third quarter of this year just because the sites had to build that infrastructure. It has gone slower than we expected. I think the fact that the CDC announced that the program is going to be re-upped for 2009 and also indicated to the jurisdictions that some of this money could be carried over into the next fiscal year has been – hasn't exactly encouraged rapid implementation by the jurisdictions. But we still think we're in very good position to capture the largest majority of this new funding. John Putnam – Dawson James: Thanks.

Your next question comes from a line of Jeff Frelick with Lazard Capital. Jeff Frelick – Lazard Capital Markets: Good evening. So, if I am understanding this correctly, maybe Ron, you are taking down the guidance by about $8 million from the, let's say, the midpoint of call it $91 million to $83 million. We kind of knew about the workplace testing slowdown and I guess the Africa purchases primarily in Madagascar. So, am I safe to assume that the bulk of the reduction is on the OTC cryosurgical business and the U.S. hospital sales?

I'd say that is correct. I'd say the cryo OTC probably accounts for about $3.5 million of the reduction and the domestic infectious disease about $2.5 million, Africa $1 million and SAT $1 million. Jeff Frelick – Lazard Capital Markets: Okay. And then, I guess we kind of thought we'd probably see the CDC funding probably show up in the ER more so even than on the public health setting given that dollars have been, I guess, kind of awarded to the jurisdictions. What's the delay? Is it just follow-up on the CDC's part to make sure that people were kind of doing what they kind of submitted in the proposal to do? And I guess if we're expecting it to kind of play out in the second, third quarters still, should that still kind of give us a little bit more confidence in the guidance, maybe not to cut it so much?

I think that you've hit the nail on the head. The CDC has not followed up on these grants and the implementation we believe as aggressively, obviously, as we would like. There's an accountability issue. The sites do have to report back to the CDC by the end of May on their program progress, how many individuals they've tested, what positivity rate they've seen, et cetera. But this is, what, eight months after the money was disbursed. And later in the call, I'll give you an update by jurisdiction as to how many sites have initiated and what we've seen so far. So, we've got a strong handle on this. The difficulty is being able to forecast what these jurisdictions are going to deliver based on the plans that clearly articulated what they said they were supposed to do. Jeff Frelick – Lazard Capital Markets: What's changing, Doug, on the Abbott's out-sales, anything changing there?

We saw significant increases in '07 versus '06 and we expected the same or similar kind of growth into 2008. That's slowed a bit right now. We're seeing a bit more competition in the hospital sector and we haven't seen quite as rapid uptake in the emergency department testing programs as we had anticipated, although we are seeing continued growth there. The CDC has doubled their efforts in terms of regional workshops, which we support and we've got a strong follow up program on that, but obviously we'd like to see more emphasis on this from Abbott. Jeff Frelick – Lazard Capital Markets: So, in the Europe, is volume slowing or is testing occurring by alternate methods?

I don't think that we are seeing the volume increase that we expected. There's some competition, but I don't think that's the major driver to the slowdown. I think we'd like to see greater adoption in the emergency department. Jeff Frelick – Lazard Capital Markets: Okay. I'll jump back in queue.

Your next question comes from the line of Dave Turkaly with SFG. Dave Turkaly – Susquehanna Financial Group: Just to push you a little, Ron, on the guidance, we are looking at $83 million for the year and we got $18 million and $18.6 million let's call it in so far. Then we're looking at an average of $23 million and change in the third and fourth. Do you expect it to sequentially pick up over third and fourth and help me get from $18.6 million broad strokes to something in the low $22 millions or wherever you think the third might be, that $3 million to $4 million sequential increase we need to hit. Where is that going to come from? Is that CDC or which part of your business?

I think it's across the number of businesses. We see the infectious disease business growing in both the third and the fourth quarter with a larger spike in the fourth quarter, which has been our pattern over the last several years. Then we also see the substance abuse business picking up a bit in Q3 to a level that we believe is a little bit more sustainable over Q2 and then in the cryo business, Dave, that's where we see a recovery from a level of about $3 million in the second quarter or slightly there, then maybe a little bit more, and then to $4 million and $5 million. So, as the cryo patterns indicate from our distribution partners, it should grow up a little over the course of the year. Dave Turkaly – Susquehanna Financial Group: Okay. Just to be clear, the infectious disease, I mean obviously the direct to U.S. health at 44 is a nice number in growth for the first quarter. Last year, you grew 30%. I'm looking at my model. I have 33% this year. I mean, if some of the spending comes on, I mean, I guess considering that's one of your bigger line items, could that be significantly stronger even than what you just reported at 45% in the first quarter, or is that sort of a high watermark and it's going to come more from cryo going forward?

We continue to believe that we will see growth in the direct to public health business largely impacted by the success of the jurisdiction in implementing the CDC initiative and how concentrated that will be in any one quarter will drive the comps. It's difficult to predict that as we have spoken about previously here, but there are good initiatives in play and we also, as Doug mentioned, have indications that the funding will be reviewed or renewed for 2009, so we continue to believe that we'll make progress in that market. We will also see, as we move out here, more of a recovery in some of the international business. Dave Turkaly – Susquehanna Financial Group: I'm not trying to – my whole thought process is you guys have a big clinical story, we'll talk about that next, and you've got the cash, so obviously there's been some challenges on the revenue side, but it's still a pretty steep increase to the back half. I just want to make sure you guys feel really comfortable with that being a kind of flattish year-over-year number. Given those challenges, it sounds like you feel pretty comfortable that some of these things will turn significantly in the third and fourth quarter.

Yes, despite the revenue guidance being $83 million and our top line last year was $83 million, don't forget we add approximately $6 million in revenues through Prestige last year as well as the $2 million in funded R&D from Schering-Plough and you back those out, still showing year on year growth with that kind of pro forma comparison. I'm not saying we are pleased to be taking our revenue number down, don't get me wrong, but we are still very bullish on the growth in our infectious disease business. It's growing nicely and we expect it will continue through the remainder of the year and in future years. Dave Turkaly – Susquehanna Financial Group: I got you. I guess onto maybe quickly to the cryo stuff, any update on the domestic side? Any color you can give us there? Are you still talking to people in terms of possibly getting a new distributor?

We have made a decision on that, Dave, and we are marching down a path. But, for competitive reasons, we're not going to disclose that path that we are on, but we fully intend to participate in this market and continue to believe it's very attractive and there's a possibility that later in the year, we'll be out. We certainly expect to be in the market for 2009. Dave Turkaly – Susquehanna Financial Group: Okay, thanks.

You're welcome.

At this time, I'd like to turn the call over to Michael Douglas. Participants please stay in queue and your questions will be answered at a later time.

Okay. Everybody knows I'm not Michael Douglas, but I want to thank you for your questions and we'll now discuss the various strategic and other business updates for this afternoon's call. Starting with our clinical development of the OraQuick HCV test, our clinical trials to support both our PMA submission to the FDA and our request for CE Mark approval in Europe are progressing very well. Both patient enrollment and testing at the several clinical sites that we've initiated are progressing and proceeding on schedule. As previously discussed, we expect these trials to continue through the second quarter of this year. Once completed, we will analyze the results and prepare our submissions. We still expect to file a PMA application with the FDA this summer and intend to submit for European approval shortly thereafter. In addition to the clinical trials, field development studies are being planned and will be executed both domestically and outside the United States in various settings where we expect significant levels of utilization. We continue to work closely with Schering-Plough in our pre-market development efforts and in building our marketing launch plans. On the OraQuick stability shelf life front, we also continue to make good progress on extending the shelf life of our OraQuick HIV test. Our real-time stability studies continue to progress and support an extension beyond six months. Product lots manufactured with certain process improvements have now completed testing after 12 months of storage and have met the performance criteria established at the start of this program. We've submitted documents to the FDA for approval of these process changes along with our stability protocol and acceptance criteria. These documents are currently under review by the FDA and we are in discussions with the agency. We'll continue with real-time stability testing over the next few…

(Operator instructions) Your next question comes from the line of Caroline Corner with Pacific Growth. Caroline Corner – Pacific Growth: Thanks for taking my call. A couple of questions, the hepatitis C progress, good to see that's on track. When you file this summer for the PMA, should we expect to see some data released around there so we can see the data that you're actually filing or is that going to be more of a case where you give it to the FDA and then we'll find out about approval?

No, I don't expect that you'll be seeing data at that time. A little bit more color on the Hep C effort. Enrollment, as I mentioned, has gone very well. All sites have been initiated and we're on schedule. Dr. Lee is planning to provide a presentation at the ASM meeting in June, I believe, and we've also been engaged in some independent studies which are very encouraging. We've had ongoing dialog with the CDC, with SAMHSA and with HHS about funding and surveillance once this product is ultimately launched, and obviously we're actively engaged with Schering. So, things are progressing on all fronts on the HCV development program and we're pretty encouraged, very excited about this. Caroline Corner – Pacific Growth: Very good. The detail you gave on the infectious disease as it pertains to the rollout within the 23 clinics that are part of the funding; you said 20 of those you are expecting to use OraQuick. It looks like they'll be putting in orders by early third quarter. Are they only using OraQuick or are they going to be using a mix? And then, what about the other three channels?

Right. Okay, so one of our challenges and this is always trying to get a handle on the incremental, right, because as I mentioned in previous calls and I think you well know, virtually every one of these jurisdictions uses OraQuick in one way, shape or form. The 14 that have ordered incremental product under this new grant, those are all using OraQuick as their primary screening tests. The four additional that I mentioned should order in Q2. They again are all using OraQuick as their primary frontline screening test and the two that will come on shortly thereafter the same thing. So, 20 of the 23 that should be up and running at least by the end of the second quarter, real early into the third, will all be using OraQuick as their primary test. The three that we are still working to secure, by the way, but they haven't committed, two of them are two of the smaller jurisdictions. One of them is one of the mid sized jurisdictions based on the grants that were offered. So, we think we're in great shape with regard to this based on our original expectations. I wish the CDC was a little bit more aggressive in demanding that these sites deliver on their grant commitments. Hopefully, with our encouragement and support, we can help them achieve those testing goals. Caroline Corner – Pacific Growth: Hopefully they will. My other question is about the litigation firm that you've selected for the Inverness lawsuit. Is this the same litigation firm that you've use previously? Then your in-house legal team at OraSure, is that still relatively intact, any new hires there, and how do you feel overall in general on the legal front?

Our in house legal team is comprised of our General Counsel and his assistant who do a great job, but for occasions like this, we seek outside counsel and support. We interviewed several IP litigation firms. We selected from the top ten in the country and they came from geographically dispersed parts of the country and we have selected one of those firms. We intend to defend this, as I mentioned, very vigorously. We believe our non-infringement and our invalidity positions are extremely strong. This is a different firm than we have ever used in the past, one that has experience in the lateral flow space and obviously has broad and deep resources in the IP litigation arena. Caroline Corner – Pacific Growth: Okay. Then a quick question, probably would have been better if I'd ask this in the first half, but with the gross margin, the increased scrap and spoilage expense, I'm assuming that's separate from the Genomma overhead issue. What is the scrap and spoilage that's affecting gross margin and is that going to be in place also going forward?

We discussed this a little bit before, Caroline that some of the issues that we were contending with in 2007, we are going to carry on into the first half of 2008 here. But what we had in the first quarter was increased spoilage related to product that we had manufactured for shipment to the international marketplace, which did not take place specifically for Madagascar and consequently we took a reserve against that product because of the change that took place so late in the quarter related to our ability to ship that product. Caroline Corner – Pacific Growth: Very good. Last question, sorry. With regard to automation of your production line, any progress there or any updates?

We intend to progress the validation of the automation system shortly. Caroline Corner – Pacific Growth: Okay. Thank you.

Your next question comes from the line of Aaron Lindberg with William Smith and Company. Aaron Lindberg – William Smith & Co.: Thank you. What is your anticipation for costs associated with the litigation with Inverness and Church & Dwight in 2008?

We have built into this a $4 million to $5 million number, Aaron. Aaron Lindberg – William Smith & Co.: Okay. And then I know that you said that you're not going to go into a ton of detail on this, but can you give us some idea as to some of the efforts that have been taken thus far to resolve this patent infringement litigation and specifically leveraging your relationship with Abbott?

It'd be inappropriate to talk about that, Aaron, but I'll say just general comments. Our position is always to see if we can arrive at a business solution to these legal disputes that work for both parties, and we're open to that. At the same time, we're going to defend our non-infringement position and enforceability of these patents aggressively. So, we'll kind of leave it at that and if we have anything material to report on developments in that regard, we'll communicate it. Aaron Lindberg – William Smith & Co.: Okay. Can you help us understand your strategy for co-marketing the HCV test with Schering-Plough both in the U.S. and outside?

We've disclosed that in previous announcements that Schering is going to detail the product to the physician office market segments worldwide. We will sell the product into those markets and we will capture 100% of revenues from those sales. Schering has agreed to a minimum number of physician detail equivalents by region and will also be obviously promoting the product and technology with the opinion leaders of, which obviously they've got a great position on a worldwide basis. Aaron Lindberg – William Smith & Co.: Can you help us understand the strategy that you guys are developing, whether you view that as developing it on your own or developing it with Schering-Plough for penetrating that market? Maybe related to that, who else are you interested in working with in regards to disturbing the rapid HCV test?

It would be inappropriate to comment on who the other potential partners are that we may or may not use in the professional channels. As we have more information to share about our marketing strategy with Schering, as we get a little bit closer to launch, we'll share that. Aaron Lindberg – William Smith & Co.: Maybe a little bit different tack on that. What progress are you making related to government funding for rapid HCV testing? That's something you've mentioned a couple times that's going to be important to that market segment.

Absolutely. We have being engaged with the CDC as well as SAMHSA and we have also been engaged with stakeholders, whether it's the National Association of State and Territorial AIDS Directors or other advocacy groups that have a high level of interest in seeing expanded HCV testing. This is another area where certainly sharing the advocacy can have a big impact. We mentioned previously that there's about five times as much HCV out there as there is HIV. It's a growing problem, not only here but throughout the world and the cost of undiagnosed and untreated HCV is extraordinary and it's only going to get worse unless we get these people diagnosed and into care. Aaron Lindberg – William Smith & Co.: Okay. A little bit different area, can you again – just on the strategy level of things, can you help us understand your progress and strategy related to expanding advanced sales internationally kind of outside of Africa and developed markets? You gave us some headlines around Europe, but what does that look like in terms of additional regulatory pathways for some of these other countries? When do we start to see some of that stuff come on line?

We did hit a bit of a bump in the road in Europe this quarter where our UK distributor actually was acquired by Inverness. So, during the course of Q1, we went out, re-canvassed the market, identified an alternative distributor who's an excellent pick and entered into discussions with them, ultimately leading to an agreement and the beginning of training that's been done, purchases have started. So, we are active in that market. As Doug has indicated, we are also about to sign a contract for a distributor in France. However, the process to ultimately generate revenues in France is one that probably will take another year or so before that really takes place. We are working and looking at distributors in Italy as well as in Germany, Aaron. Aaron Lindberg – William Smith & Co.: Okay. Is Inverness going to be selling another cryo product, a competing product in the UK, do you know?

Cryo or HCV? Aaron Lindberg – William Smith & Co.: Sorry, rapid HIV.

Yes, they have the Determine product that they acquired from Abbott a few years back, you may recall. Aaron Lindberg – William Smith & Co.: Yes. Interesting. Okay. Thank you.

You're welcome.

Your next question comes from the line of John Putnam with Dawson James.

Hey, John. John Putnam – Dawson James: -- or Doug, you never really quantified how much in terms of dollars that is – can you help us out there?

John, I missed the first part of your question, sorry. John Putnam – Dawson James: On the SAMHSA discussion, you talked about the number of jurisdictions, but you never really quantified the amount of dollars involved in this effort, can you help us out with that?

The total funding was approximately to $400,000 to $500,000 per grantee. The total funding is $31 million per year over five years. So the total funding, I believe, was in the $160 million range per year over five years. John Putnam – Dawson James: So, that's really almost as much as the CDC's one year commitment, wasn't it, which is, what, $35 million?

Annually, the SAMHSA number is just under the CDC number, but unlike the CDC initiative, these monies can be used for multiple other activities and it doesn't have the high level of focus on testing as the CDC initiative has, John.

Hey, John, let me be crystal clear. The SAMHSA awarded 67 grantees $31.8 million in year one of a five year project. Okay? So, there's an anticipation that that $31.8 million will be made available each of the remaining four years. John Putnam – Dawson James: Okay. But it doesn't all go into testing necessarily?

That's correct again. So, it's up to a site by site decision as to how they use that funding, but it's encouraged for testing and I gave you the statistics on the number of sites out of those 67 that are currently using our product and that are currently testing. SAMHSA is talking about additional programs with the additional monies that are going to be earmarked specifically for testing. We believe that's going to present additional opportunities to the even larger base of their grantees and we are talking with them about the structure of that program and what that might look like. John Putnam – Dawson James: Are these grantees jurisdictions or are they private organizations or municipal organizations?

They're typically local service providers that are providing either substance abuse or mental health services and receive some level of SAMHSA grant funding. Many of them are drug treatment centers. John Putnam – Dawson James: Okay.

Your next question comes from the line of Dave Turkaly with SIG. Dave Turkaly – Susquehanna Financial Group: One quick one on the Hep C product you submit this summer, best estimate if you're willing to share in terms of when that product could be launched?

As soon as it's approved. Dave Turkaly – Susquehanna Financial Group: It looks like you could benefit from a new product. Just to be fair, the OraQuick is still growing nice, but gosh, the substance abuse and cryo had some issues, so I'm just trying to get a first cut at when another big opportunity comes on line for you.

Absolutely, and Hepatitis C represents one of those. As I said, our intention is to make our submission later on this summer and generally it's a 6 to 12 month process assuming things are in order. We'd expect that based on the preclinical work that was done that we're going to have a solid submission and hopefully FDA will review that rapidly. We will also be making our submission for European approval shortly after we apply to the FDA and generally that's a faster review time. Dave Turkaly – Susquehanna Financial Group: Okay. Thanks.

At this time, there are no further questions.

Okay. Let me just take the opportunity to thank everyone for participating in today's call. Obviously, there's several challenges facing our business at the moment and we are focused and I assure you we will address them. At the same time, our OraQuick business continues to grow nicely and we are making excellent progress in our clinical development efforts. So, as you know, the management team and I remain committed to a very successful 2008 and to delivering significant value to our stockholders. So, I thank you again and wish you all a good afternoon and evening. Good night.

This concludes today's conference call. You may now disconnect.